Raloxifene Hydrochloride

Raloxifene hydrochloride is a selective estrogen receptor modulator (SERM) used in the treatment and prevention of osteoporosis in postmenopausal women. It mimics the effects of estrogen on bone tissue, reducing bone resorption and increasing bone density.

Indications

-Prevention and treatment of osteoporosis in postmenopausal women -Reduction of risk of invasive breast cancer in postmenopausal women with osteoporosis or at high risk of breast cancer

Dosage

-For osteoporosis: 60 mg orally once daily, with or without food. -For reduction of breast cancer risk: Same dosage as for osteoporosis.

Contra-Indications

-Hypersensitivity to raloxifene or any component of the formulation -Pregnancy and lactation -History of venous thromboembolism (VTE) -Active or past history of liver disease

Special Precautions

-Use with caution in women with a history of VTE, stroke, or coronary artery disease. -Discontinue use at least 72 hours before and during prolonged immobilization. -Monitor for signs of VTE, including leg pain or swelling, chest pain, shortness of breath, or visual disturbances. -Consider discontinuation if significant bone loss occurs. -Perform regular breast and gynecological examinations. -Caution in patients with renal impairment; dosage adjustment may be necessary.

Side Effects

-Hot flashes -Leg cramps -Peripheral edema -Arthralgia -Increased risk of VTE, including deep vein thrombosis and pulmonary embolism -Increased risk of stroke -Increased risk of endometrial cancer -Increased triglycerides -Headache -Sinusitis

Drug Interactions

-Cholestyramine: May decrease raloxifene absorption; administer at least 1 hour apart. -Warfarin: Raloxifene may increase the anticoagulant effect; monitor INR closely. -Estrogen-containing products: Concurrent use may decrease the effectiveness of raloxifene. -Thyroid hormones: May decrease the effectiveness of raloxifene.